13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01879202 (ClinicalTrials.gov) | December 2012 | 7/11/2012 | Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis | Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study. | Multiple Sclerosis;Fatigue | Drug: Methylphenidate modified release;Drug: Maltodextrin | Medical University of Vienna | NULL | Recruiting | 18 Years | N/A | Both | 96 | Phase 2 | Austria |